News

News Archive

Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC)

Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC)

FLORENCE, Italy and NEW YORK, December 11, 2023 – The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and...
Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer

Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer

FLORENCE, Italy and NEW YORK, December 8, 2023 – The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and...
Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology

Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology

FLORENCE, Italy and NEW YORK, Nov. 20, 2023 -- The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, and Stemline...
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

FLORENCE (Italy) and HONG KONG (China), November 7, 2023 – The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and SciClone...
European Organisation for Research and Treatment of Cancer & the Menarini Group Launch New Clinical Trial in Early-Stage Breast Cancer

European Organisation for Research and Treatment of Cancer & the Menarini Group Launch New Clinical Trial in Early-Stage Breast Cancer

Brussels (Belgium) and Florence (Italy), 19 October 2023 – The European Organisation for Research and Treatment of Cancer (EORTC) and the Menarini Group (Menarini), a leading...
The 2023 Season gets underway for the  Volpi Rosse Menarini Wheelchair Basketball Team

The 2023 Season gets underway for the Volpi Rosse Menarini Wheelchair Basketball Team

The Volpi Rosse Menarini are once again setting their sights on the net, as the wheelchair basketball team takes to the court for the start of a new season in the Serie A FIPIC National...
12345

Select a Year from the Archive

Our values

Our values

Everyday we put our values into action. 4 values, which have given life to Menarini and have shaped its history.

Read More

Our values

Go to Follow our blog

Follow our blog

Discover our stories from all over the world

Read More